Governor Newsom Releases Master Plan for Tackling the Fentanyl and Opioid Crisis

Governor Newsom has invested over $1 billion to tackle the crisis
Through CalRx, California will seek to manufacture its own Naloxone
Master Plan provides comprehensive approach to save more lives

SAN DIEGO COUNTY – Today, following a visit to the San Ysidro Port of Entry, Governor Gavin Newsom released his administration’s Master Plan for Tackling the Fentanyl and Opioid Crisis. Recognizing the opioid and fentanyl crisis as a multifaceted public health and public safety issue, Governor Newsom’s Master Plan provides a comprehensive approach to save lives. The Master Plan builds on the Governor’s $1 billion investment to tackle this crisis — including an expansion of California National Guard-supported operations that last year led to a 594% increase in seized fentanyl. The Master Plan outlines aggressive steps to support overdose prevention efforts, hold the opioid pharmaceutical industry accountable, crack down on drug trafficking, and raise awareness about the dangers of opioids, including fentanyl.

WHAT GOVERNOR NEWSOM SAID: “Over 150 people die every day in our nation from overdoses and poisonings related to synthetic opioids like fentanyl. Enough. With this Master Plan, California is doubling down to combat this crisis and save lives. Our comprehensive approach will expand enforcement efforts to crack down on transnational criminal organizations trafficking this poison into our communities — while prioritizing harm reduction strategies to reduce overdoses and compassionately help those struggling with substance use and addiction.”
View the Master Plan

DEA Announces Important Change to Registration Requirement

On December 29, 2022, with the signing of the Consolidated Appropriations Act of 2023 (the Act), Congress eliminated the “DATA-Waiver Program.”

All DEA registrants should be aware of the following:

  • A DATA-Waiver registration is no longer required to treat patients with buprenorphine for opioid use disorder.
  • Going forward, all prescriptions for buprenorphine only require a standard DEA registration number. The previously used DATA-Waiver registration numbers are no longer…

End of Buprenorphine X-Waiver

After almost twenty years of intense medication specific government regulation buprenorphine is now just like other schedule III medications. The era of limited numbers of treatment slots that started at 30 patients per provider who had completed 8 hours of specific training, requirements to maintain lists of patients who received prescriptions and even in person visits by DEA agents to a large…

Retirement Announcement

Dear CSAM Members:

I recently announced to the CSAM Board of Directors that I will retire from my position as CSAM’s Executive Director effective January 16, 2020.

I have had the honor of serving in this role since January 1, 2000 upon the retirement of CSAM’s first Executive Director Gail Jara. The decision to leave this position was not an easy one. It has been an honor to work with such a wonderfully supportive team comprised of board leaders, members, and staff, and I will always hold warm memories in my heart for the experiences we have shared.

Between now and January, I will be working to ensure that the activities currently underway are transitioned to the new Executive Director to be selected by the CSAM Board of Directors. Thank you for supporting me over the past 20 years, and thank you for supporting CSAM.

With deepest appreciation and respect,

Kerry Parker, CAE